NYX-2925

NYX-2925
Clinical data
Drug classSelective NMDA receptor modulator
ATC code
  • None
Legal status
Legal status
Identifiers
  • (2S,3R)-3-hydroxy-2-[(4R)-5-(2-methylpropanoyl)-3-oxo-2,5-diazaspiro[3.4]octan-2-yl]butanamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC14H23N3O4
Molar mass297.355 g·mol−1
3D model (JSmol)
  • C[C@H]([C@@H](C(=O)N)N1C[C@@]2(C1=O)CCCN2C(=O)C(C)C)O
  • InChI=1S/C14H23N3O4/c1-8(2)12(20)17-6-4-5-14(17)7-16(13(14)21)10(9(3)18)11(15)19/h8-10,18H,4-7H2,1-3H3,(H2,15,19)/t9-,10+,14-/m1/s1
  • Key:NFXPEHLDVKVVKA-ISTVAULSSA-N

NYX-2925 is a compound derived from rapastinel which acts as a positive allosteric modulator of the NMDA receptor. It has been researched as a potential antidepressant and treatment for neuropathic pain.[1][2][3][4][5]

References

  1. ^ Khan MA, Houck DR, Gross AL, Zhang XL, Cearley C, Madsen TM, et al. (March 2018). "NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory". The International Journal of Neuropsychopharmacology. 21 (3): 242–254. doi:10.1093/ijnp/pyx096. PMC 5838819. PMID 29099938.
  2. ^ Ghoreishi-Haack N, Priebe JM, Aguado JD, Colechio EM, Burgdorf JS, Bowers MS, et al. (September 2018). "NYX-2925 Is a Novel N-Methyl-d-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain". The Journal of Pharmacology and Experimental Therapeutics. 366 (3): 485–497. doi:10.1124/jpet.118.249409. PMID 29986951.
  3. ^ Morrison G, Asiedu MN, Priebe JM, Dunning J, Ghoreishi-Haack N, Kroes RA, et al. (2020). "The NMDAR modulator NYX-2925 alleviates neuropathic pain via a Src-dependent mechanism in the mPFC". Neurobiology of Pain. 7 100039. doi:10.1016/j.ynpai.2019.100039. PMC 6938954. PMID 31909296.
  4. ^ Bowers MS, Cacheaux LP, Sahu SU, Schmidt ME, Sennello JA, Leaderbrand K, et al. (March 2020). "NYX-2925 induces metabotropic N-methyl-d-aspartate receptor (NMDAR) signaling that enhances synaptic NMDAR and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor". Journal of Neurochemistry. 152 (5): 523–541. doi:10.1111/jnc.14845. PMC 7065110. PMID 31376158.
  5. ^ Zeng Y, Qu ZY, Zhu QW, Wang HY, Zhou Y, Gao ZB (January 2026). "New advances in small molecule drugs targeting NMDA receptors". Acta Pharmacologica Sinica. 47 (1): 3–21. doi:10.1038/s41401-025-01675-8. PMC 12764577. PMID 41188625.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.